
AI-powered Generate Biomedicines targets record biotech IPO with a $400M raise
Generate Biomedicines is launching an Nasdaq IPO by selling 25 million shares at $16 (potentially up to 3.75 million more shares), targeting about $400 million in proceeds and up to $460 million with the underwriters’ option. The funds will advance Phase 3 asthma trials for its AI-designed GB-0895 and support other programs, as investor interest in biotech IPOs rebounds. The company emphasized its AI-driven drug discovery platform and partnerships with Amgen and Novartis, while aiming for capital efficiency amid a renewed funding environment.
